Injectable drug product recalled due to sterility assurance failure
Pharmacy Innovations is recalling injectable glycerin/lidocaine/epinephrine products nationwide due to lack of sterility assurance. FDA inspection found insanitary conditions at the manufacturing facility.
What this means for you
Real risk of harm even if no illness or injury has been reported yet. Stop using the product and follow the agency's guidance.
Our severity reasoning: FDA Class II recall with theoretical sterility hazard and no reported illnesses or injuries. The facility inspection findings establish a risk-of-harm condition without actual harm reported, warranting a High severity rating per the rubric.
Plain-English summary
Pharmacy Innovations, located in Erie, Pennsylvania, is recalling injectable glycerin/lidocaine/epinephrine products (available in two formulations) distributed nationwide. The recall is due to lack of assurance of sterility.
During an FDA inspection, the agency identified insanitary conditions at the manufacturing facility. These conditions raised concerns that the injectable products may not meet required sterility standards necessary for safe use.
Healthcare providers and patients should discontinue use of affected products. If you believe you have received affected medication, contact your healthcare provider or pharmacy for guidance. Affected lot codes are t20221116@36 and t20221117@11.
The recalled product
- Product
- GLYCERIN/LIDOCAINE HCL/EPINEPHRINE 31%(V/V)/0.17%/0.00017% (10ML VIALS); GLYCERIN/LIDOCAINE HCL/EPINEPHRINE 48.7%(W/V)/0.67%/0.00067% (10ML VIAL) INJECTABLE, Rx Only, Pharmacy Innovations, 2936 W 17th St., Erie, PA.
- Manufacturer
- Pharmacy Innovations
- Category
- Drug — Injectable
- Hazard
- sterility-failure
- contamination-risk
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (1)
- t20221116@36 t20221117@11
Distribution
Distributed nationwide across the United States.
Related recalls
Same category
- CriticalWarfarin Tablets Recalled After Mix-Up Between 2.5 mg and 5 mg Strengths
FDA (Drugs) · 2026-07-21
- ModerateFDA Recalls Pred Mild Ophthalmic Suspension Due to Failed Stability Specifications
FDA (Drugs) · 2026-06-03
- ModerateNicotine Transdermal System Patches Recalled for Oxidative Impurity Specification Failure
FDA (Drugs) · 2026-06-03
- LowPrimidone Tablets Recalled Due to Cross-Contamination with Acemetacin
FDA (Drugs) · 2026-05-27
- HighLiraglutide Injection Recalled Due to Particulate Matter in Cartridges
FDA (Drugs) · 2026-05-27